- Home
- SGMO vs DCTH Comparison
SGMO vs DCTH Comparison
Compare SGMO & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- DCTH
- Stock Information
- Founded
- SGMO 1995
- DCTH 1988
- Country
- SGMO United States
- DCTH United States
- Employees
- SGMO N/A
- DCTH N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- DCTH Medical/Dental Instruments
- Sector
- SGMO Health Care
- DCTH Health Care
- Exchange
- SGMO Nasdaq
- DCTH Nasdaq
- Market Cap
- SGMO 488.2M
- DCTH 518.0M
- IPO Year
- SGMO 2000
- DCTH N/A
- Fundamental
- Price
- SGMO $1.13
- DCTH $14.98
- Analyst Decision
- SGMO Buy
- DCTH Strong Buy
- Analyst Count
- SGMO 5
- DCTH 4
- Target Price
- SGMO $5.20
- DCTH $22.25
- AVG Volume (30 Days)
- SGMO 10.5M
- DCTH 407.3K
- Earning Date
- SGMO 03-12-2025
- DCTH 11-08-2024
- Dividend Yield
- SGMO N/A
- DCTH N/A
- EPS Growth
- SGMO N/A
- DCTH N/A
- EPS
- SGMO N/A
- DCTH N/A
- Revenue
- SGMO $52,291,000.00
- DCTH $22,644,000.00
- Revenue This Year
- SGMO N/A
- DCTH $1,605.13
- Revenue Next Year
- SGMO $5.97
- DCTH $111.67
- P/E Ratio
- SGMO N/A
- DCTH N/A
- Revenue Growth
- SGMO N/A
- DCTH 945.91
- 52 Week Low
- SGMO $0.30
- DCTH $3.70
- 52 Week High
- SGMO $3.18
- DCTH $15.05
- Technical
- Relative Strength Index (RSI)
- SGMO 37.01
- DCTH 73.66
- Support Level
- SGMO $1.00
- DCTH $12.14
- Resistance Level
- SGMO $1.18
- DCTH $12.98
- Average True Range (ATR)
- SGMO 0.15
- DCTH 0.82
- MACD
- SGMO -0.04
- DCTH 0.23
- Stochastic Oscillator
- SGMO 13.84
- DCTH 97.93
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.